Published in PLoS One on February 20, 2014
MicroRNAome genome: a treasure for cancer diagnosis and therapy. CA Cancer J Clin (2014) 1.40
Dysregulation of microRNAs in breast cancer and their potential role as prognostic and predictive biomarkers in patient management. Breast Cancer Res (2015) 1.12
Serum microRNA-210 as a potential noninvasive biomarker for the diagnosis and prognosis of glioma. Br J Cancer (2015) 0.97
Diagnostic value of a plasma microRNA signature in gastric cancer: a microRNA expression analysis. Sci Rep (2015) 0.93
The role of hypoxia-induced miR-210 in cancer progression. Int J Mol Sci (2015) 0.91
An ER-associated miRNA signature predicts prognosis in ER-positive breast cancer. J Exp Clin Cancer Res (2014) 0.89
A direct plasma assay of circulating microRNA-210 of hypoxia can identify early systemic metastasis recurrence in melanoma patients. Oncotarget (2015) 0.88
Prognostic Impact of Hypoxia-Inducible miRNA-210 in Patients with Lung Adenocarcinoma. J Oncol (2015) 0.88
MicroRNA networks regulated by all-trans retinoic acid and Lapatinib control the growth, survival and motility of breast cancer cells. Oncotarget (2015) 0.86
MicroRNAs, TGF-β signaling, and the inflammatory microenvironment in cancer. Tumour Biol (2015) 0.84
Prediction of poor prognosis in breast cancer patients based on microRNA-21 expression: a meta-analysis. PLoS One (2015) 0.83
The predictive effect of overexpressed miR-34a on good survival of cancer patients: a systematic review and meta-analysis. Onco Targets Ther (2015) 0.78
Diagnostic and prognostic accuracy of miR-21 in renal cell carcinoma: a systematic review protocol. BMJ Open (2016) 0.77
Hypoxia-related microRNA-210 is a diagnostic marker for discriminating osteoblastoma and osteosarcoma. J Orthop Res (2016) 0.76
Expression of miR-210 in relation to other measures of hypoxia and prediction of benefit from hypoxia modification in patients with bladder cancer. Br J Cancer (2016) 0.75
ApoptomiRs of Breast Cancer: Basics to Clinics. Front Genet (2016) 0.75
MicroRNAs in the pathobiology of sarcomas. Lab Invest (2015) 0.75
Fibroblast miR-210 overexpression is independently associated with clinical failure in Prostate Cancer - a multicenter (in situ hybridization) study. Sci Rep (2016) 0.75
Hypoxia-regulated gene expression explains differences between melanoma cell line-derived xenografts and patient-derived xenografts. Oncotarget (2016) 0.75
Angiomirs expression profiling in diffuse large B-Cell lymphoma. Oncotarget (2016) 0.75
MicroRNA-210-mediated proliferation, survival, and angiogenesis promote cardiac repair post myocardial infarction in rodents. J Mol Med (Berl) (2017) 0.75
The MicroRNA miR-210 Is Expressed by Cancer Cells but Also by the Tumor Microenvironment in Triple-Negative Breast Cancer. J Histochem Cytochem (2017) 0.75
Bias in meta-analysis detected by a simple, graphical test. BMJ (1997) 122.24
The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell (1993) 64.62
Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA (2000) 55.37
MicroRNA signatures in human cancers. Nat Rev Cancer (2006) 46.29
Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A (2002) 32.26
Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med (1998) 19.07
Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol (2008) 10.28
A microRNA signature of hypoxia. Mol Cell Biol (2006) 7.24
Molecular views of recombination proteins and their control. Nat Rev Mol Cell Biol (2003) 6.96
hsa-miR-210 Is induced by hypoxia and is an independent prognostic factor in breast cancer. Clin Cancer Res (2008) 4.84
MicroRNA-210 modulates endothelial cell response to hypoxia and inhibits the receptor tyrosine kinase ligand Ephrin-A3. J Biol Chem (2008) 4.69
MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. Oncogene (2007) 4.46
miR-210 links hypoxia with cell cycle regulation and is deleted in human epithelial ovarian cancer. Cancer Biol Ther (2007) 3.93
Hypoxia-inducible mir-210 regulates normoxic gene expression involved in tumor initiation. Mol Cell (2009) 3.68
E2F3 activity is regulated during the cell cycle and is required for the induction of S phase. Genes Dev (1998) 3.48
Elevated expression of microRNAs 155, 203, 210 and 222 in pancreatic tumors is associated with poorer survival. Int J Cancer (2010) 3.11
MicroRNA miR-210 modulates cellular response to hypoxia through the MYC antagonist MNT. Cell Cycle (2009) 3.07
Iron-sulfur cluster biogenesis and human disease. Trends Genet (2008) 3.03
MicroRNA regulation of DNA repair gene expression in hypoxic stress. Cancer Res (2009) 2.93
CDC25A phosphatase is a target of E2F and is required for efficient E2F-induced S phase. Mol Cell Biol (1999) 2.84
Ischemic preconditioning augments survival of stem cells via miR-210 expression by targeting caspase-8-associated protein 2. J Biol Chem (2009) 2.66
MicroRNA-210 as a novel therapy for treatment of ischemic heart disease. Circulation (2010) 2.32
Identification of a microRNA panel for clear-cell kidney cancer. Urology (2009) 2.32
Circulating miR-210 predicts survival in critically ill patients with acute kidney injury. Clin J Am Soc Nephrol (2011) 2.27
Hypoxia inducible microRNA 210 attenuates keratinocyte proliferation and impairs closure in a murine model of ischemic wounds. Proc Natl Acad Sci U S A (2010) 2.11
miR-210 is overexpressed in late stages of lung cancer and mediates mitochondrial alterations associated with modulation of HIF-1 activity. Cell Death Differ (2010) 2.09
Breast cancer signatures for invasiveness and prognosis defined by deep sequencing of microRNA. Proc Natl Acad Sci U S A (2012) 2.07
Interactions of miR-323/miR-326/miR-329 and miR-130a/miR-155/miR-210 as prognostic indicators for clinical outcome of glioblastoma patients. J Transl Med (2013) 2.04
hsa-mir-210 is a marker of tumor hypoxia and a prognostic factor in head and neck cancer. Cancer (2010) 1.95
MicroRNA expression analysis in triple-negative (ER, PR and Her2/neu) breast cancer. Cell Cycle (2011) 1.90
An integrated approach for experimental target identification of hypoxia-induced miR-210. J Biol Chem (2009) 1.90
Hypoxia-regulated microRNA-210 modulates mitochondrial function and decreases ISCU and COX10 expression. Oncogene (2010) 1.88
MicroRNA-210 regulates cancer cell proliferation through targeting fibroblast growth factor receptor-like 1 (FGFRL1). J Biol Chem (2010) 1.76
Global microRNA expression profiling identifies MiR-210 associated with tumor proliferation, invasion and poor clinical outcome in breast cancer. PLoS One (2011) 1.72
Circulating miRNAs as surrogate markers for circulating tumor cells and prognostic markers in metastatic breast cancer. Clin Cancer Res (2012) 1.63
miR-210: the master hypoxamir. Microcirculation (2012) 1.56
miR-210 promotes osteoblastic differentiation through inhibition of AcvR1b. FEBS Lett (2009) 1.46
The VHL-dependent regulation of microRNAs in renal cancer. BMC Med (2010) 1.46
MiR-210 promotes a hypoxic phenotype and increases radioresistance in human lung cancer cell lines. Cell Death Dis (2013) 1.37
A specific miRNA signature correlates with complete pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys (2011) 1.30
Serum miR-210 as a novel biomarker for molecular diagnosis of clear cell renal cell carcinoma. Exp Mol Pathol (2012) 1.23
miR-210 is a target of hypoxia-inducible factors 1 and 2 in renal cancer, regulates ISCU and correlates with good prognosis. Br J Cancer (2013) 1.21
Expression of miR-210 during erythroid differentiation and induction of gamma-globin gene expression. BMB Rep (2009) 1.20
MicroRNAs and the skin: tiny players in the body's largest organ. J Dermatol Sci (2008) 1.20
Differential expression profiles of microRNAs as potential biomarkers for the early diagnosis of esophageal squamous cell carcinoma. Oncol Rep (2012) 1.16
miRNA expressions in rectal cancer as predictors of response to neoadjuvant chemoradiation therapy. Int J Colorectal Dis (2012) 1.16
Overexpression of miR-210, a downstream target of HIF1α, causes centrosome amplification in renal carcinoma cells. J Pathol (2011) 1.12
miR-210 activates notch signaling pathway in angiogenesis induced by cerebral ischemia. Mol Cell Biochem (2012) 1.06
Diagnostic and prognostic potential of differentially expressed miRNAs between metastatic and non-metastatic renal cell carcinoma at the time of nephrectomy. Clin Chim Acta (2012) 1.05
HOXA1-stimulated oncogenicity is mediated by selective upregulation of components of the p44/42 MAP kinase pathway in human mammary carcinoma cells. Oncogene (2007) 1.05
Survival of hypoxic human mesenchymal stem cells is enhanced by a positive feedback loop involving miR-210 and hypoxia-inducible factor 1. J Vet Sci (2013) 1.02
Up-regulation of miR-210 by vascular endothelial growth factor in ex vivo expanded CD34+ cells enhances cell-mediated angiogenesis. J Cell Mol Med (2012) 1.01
Rad52. Curr Biol (2009) 1.00
Prognostic significance of metastasis-related microRNAs in early breast cancer patients with a long follow-up. Clin Chem (2013) 1.00
Expression of microRNA 210 associates with poor survival and age of tumor onset of soft-tissue sarcoma patients. Int J Cancer (2011) 0.99
miR-210 suppresses BNIP3 to protect against the apoptosis of neural progenitor cells. Stem Cell Res (2013) 0.97
Prognostic evaluation of microRNA-210 expression in pediatric osteosarcoma. Med Oncol (2013) 0.95
The E2F-family proteins induce distinct cell cycle regulatory factors in p16-arrested, U343 astrocytoma cells. Oncogene (1998) 0.93
Differential expression profiling of microRNAs and their potential involvement in esophageal squamous cell carcinoma. Tumour Biol (2013) 0.92
High expression of microRNA-210 is an independent factor indicating a poor prognosis in Japanese triple-negative breast cancer patients. Jpn J Clin Oncol (2012) 0.92
TLR3-induced placental miR-210 down-regulates the STAT6/interleukin-4 pathway. PLoS One (2013) 0.89
miR-210: a therapeutic target in cancer. Expert Opin Ther Targets (2012) 0.87
Survivin-miRNA-loaded nanoparticles as auxiliary tools for radiation therapy: preparation, characterisation, drug release, cytotoxicity and therapeutic effect on colorectal cancer cells. J Microencapsul (2012) 0.77